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Conclusions: This is the ﬁrst study to demonstrate that higher BMD in
men and women is associated with tibiofemoral cartilage loss on MRI
in knees without RKOA, including K-L grade 0 knees. We also conﬁrm
previous ﬁndings from radiographs in this cohort that BMD is weakly,
or not all, associated with structural progression in knees with existing
RKOA.
Table. BMD quartiles and relative risk of cartilage loss, by baseline K-L grade
Baseline K-L 0−1 Baseline K-L 2−3
N (%) of
subregions
with CL
RR (95%CI)
for CL
N (%) of
subregions
with CL
RR (95%CI)
for CL
FN BMD quartile
Q1-lowest 39 (3.9) 1.0 ref 61 (7.4) 1.0 ref
Q2 75 (7.7) 2.0 (1.1, 3.8) 60 (6.8) 1.0 (0.6, 1.6)
Q3 49 (5.4) 1.3 (0.7, 2.7) 93 (9.8) 1.4 (0.9, 2.2)
Q4-highest 73 (7.5) 2.1 (1.1, 4.1) 80 (9.2) 1.4 (0.9, 2.2)
P-value trend 0.084 0.080
Q 2−4 vs Q1 197 (6.9) 1.8 (1.03, 3.2) 233 (8.6) 1.2 (0.8, 1.8)
Whole body BMD quartile
Q1-lowest 37 (4.2) 1.0 ref 68 (7.3) 1.0 ref
Q2 59 (5.5) 1.4 (0.7, 2.6) 73 (9.6) 1.3 (0.8, 2.0)
Q3 60 (6.1) 1.6 (0.9, 3.1) 73 (8.5) 1.2 (0.7, 1.8)
Q4-highest 80 (8.9) 2.5 (1.3, 4.7) 77 (8.2) 1.1 (0.7, 1.8)
P-value trend 0.001 0.791
Q 2−4 vs Q1 199 (6.7) 1.7 (1.05, 3.0) 223 (8.7) 1.2 (0.8, 1.8)
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Purpose: In the present study we will test the preventive effect of a tailor
made intervention for reducing weight as well as of an intervention with
oral crystalline glucosamine sulphate in a factorial design in a high-risk
group of overweight middle aged women who have not yet consulted for
knee osteoarthritis (OA).
Methods: 40 general practitioners (GPs) will contact all registered women
between 50 and 60 years of age without major co-morbidities. After
telephonic screening, 400 women with a BMI  27 who have not yet
consulted for knee pain will be included in this study. At baseline, X-rays
and MRIs will be made of both knees to measure presence and amount of
OA features. Presence of radiological signs indicating knee OA (Kellgren-
Lawrence index of 2 or more) and knee OA according to the ACR criteria
are exclusion criteria. From serum and urine samples serum glucose,
serum cholesterol, levels of bone and cartilage degeneration markers and
inﬂammation markers will be determined. Through physical examination
weight, length, blood pressure, skin fold, pain on pressure of the joint
margins, and crepitation of the knee joint will be measured. All participants
ﬁll in a questionnaire to measure knee complaints (WOMAC), activity level
(SQUASH), menopausal status, co-morbidity, medical consumption, co-
interventions, and quality of live (Euroqol).
After baseline measurements, participants will be randomised over four
groups. Half of all participants will be allocated to a tailor made interven-
tion of half a year to reduce weight (consisting of physical activity classes
and several consultations with a dietician); the other half will not receive
this intervention. Secondly, in both groups half of the participants will
be randomised to receive 1500mg oral crystalline glucosamine sulphate
once a day for two and a half year while the other half will receive
a placebo. After two and a half year, baseline measurements will be
repeated. The full-scale trial was preceded by a pilot trial. In this feasibility
trial procedures, compliance and effects of the intervention were tested
during a one year follow-up.
Results: 1365 women were contacted by 10 GPs. Of these 353 women
returned a response to our research centre (26%). 184 were excluded
after telephonic screening because they did not meet the inclusion criteria
(52%). Of the remaining 93 (55%) were willing to participate and were
included in the study and followed for one year according the above-
mentioned protocol.
After 6 months, 89% of the participants had taken more than 75% of the
glucosamine or placebo. At the end of the feasibility study, 73% of the
women allocated to the tailor made intervention have visited the physical
activity classes and 84% of them had al least one consultation with the
dietician. 28% of the women in the weight reduction group showed a
weight reduction of 5 kg and/or 5% reduction of the baseline weight
versus 13% in the other group. At one year, only 4% is lost to follow-
up. On the baseline MRIs, 20% of the women showed osteochondral
defects on the patella and 10% on the medial and lateral condyle of the
femur. Osteophytes were found on the patella and on the lateral and
medial condyle of the femur (all in 10% of the women). Over 50% of the
women showed degeneration of the medial meniscus and 35% of the
lateral meniscus. At one year follow-up, 5% of the cases or less showed
progression of the knee OA related features on the MRIs.
Conclusions: Based on the results of the pilot trial, a full-scale trial
seems to be feasible. Therefore all participants of the pilot trial will be
followed for another one and a half year and 307 new participants will be
gathered according to above-mentioned protocol.
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Purpose: The objective of our study was to explore the (OA) of the knee,
hip, hand, and in vertebral OA.
Methods: We performed a retrospective study involving 497 patients
who did receive a chondroprotective treatment [Glucosamine 500mg +
Chondroitin-sulphate (CSbBio-ActiveTM) 500mg), and native collagen
type II (1mg) once a day] for their painful osteoarthritis during 12 months.
Knee OA was present in 234 pts, hip OA in 78, hand OA in 124, cervical
OA in 26 and lumbar OA in 35 pts. For deﬁning treatment adherence
levels, a self reported information recorded on patient’s ﬁle was examined
and a cut-off of 70% was established.
Adherence to chondroprotective treatment in OA.
Results: During the 12 months of observation, the level of adherence
>70% was maintained for 22/78 of hip OA, 185/234 for knee OA, 10/26
for cervical OA, 15/35 for lumbar OA and 98/124 for hand OA; the overall
number of adherents was 330 and 167 discontinued the chondroprotec-
tive treatment. Patients affected with peripheral OA did maintain the >70%
treatment adherence greater than pts with vertebral OA (p> 0.01). The
difference between hip sufferers and knee sufferers was signiﬁcant. The
difference between hand and knee sufferers was not signiﬁcant.
Conclusions: People who are prescribed self-administered medications
generally take less than the prescribed doses. Increasing adherence to
medications might improve the beneﬁts, but also might increase adverse
effects of medications. This is not the case of chondroprotective treat-
ment, which has in toxicology studies an excellent tolerance proﬁle. In our
observation, a quite satisfactory adherence was present only in sufferers
of knee OA and hand OA. Ameliorating adherence may possibly improve
patient outcomes.
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Purpose: To estimate the average cost per patient with osteoarthritis,
treated with CS or NSAID for 6 months, and the possible consequences
that the reduction on the consumption of NSAID due to CS treatment
may have on the budget impact for the Spanish National Health System
(NHS).
